David A. Gonyer - 08 Feb 2023 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role
CEO, Director
Signature
/s/ Matthew J. D'Onofrio, Attorney-in-fact for David A. Gonyer
Issuer symbol
EVOK
Transactions as of
08 Feb 2023
Net transactions value
$0
Form type
4
Filing time
10 Feb 2023, 15:13:14 UTC
Previous filing
04 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVOK Stock Option (Right to Buy) Award $0 +30,000 $0.000000 30,000 08 Feb 2023 Common Stock 30,000 $4.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2023, subject to the reporting person's continuous service to the issuer on each such vesting date.